EGFR Mutant NSCLC Post Osimertinib
Podcast | English | 31 Min
Image For Activity Cover
No Credit Offered
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a new Virtual Tumor Board on EGFR mutant NSCLC and acquired resistance. Dr. Liu is joined by two thoracic medical oncologists, Dr. Xiuning Le and Dr. Hidehito Horinouchi, both global experts in targeted therapy.

Podcast Hosts:

  • Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA 

Podcast Guests: 

  • Hidehito Horinouchi, MD, PhD, Assistant Chief of the Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
  • Xiuning Le, MD, PhD, Assistant Professor in the Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Powered By